![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Vol. 61, Issue 6, 1297-1302, June 2002
ACADIA Pharmaceuticals, Inc., San Diego, California (T.A.S., C.T.,
N.S., T.L.M., E.A.C., E.S.B., D.L., U.H., M.R.B.); and Department of
Pharmacology, University of California at San Diego, San Diego,
California (M.R.B.)
Receptors have well-conserved regions that are recognized and activated
by hormones and neurotransmitters. Most drugs bind to these sites and
mimic or block the action of the native ligands. Using a
high-throughput functional screen, we identified a potent and selective
M1 muscarinic receptor agonist from a novel structural class. Using a series of chimeric receptors, we demonstrated that this
ligand activates the receptor through a region that is not conserved
among receptor subtypes, explaining its unprecedented selectivity. This
region of the receptor is distinct from the conserved region that is
recognized by traditional ligands. The finding that receptors for
small-molecule transmitters can have multiple, structurally distinct
activation sites has broad implications for the study of receptor
structure/function and the potential for the discovery of novel ligands
with high selectivity.
This article has been cited by other articles:
|
|
 |
|
  J. E. Marlo, C. M. Niswender, E. L. Days, T. M. Bridges, Y. Xiang, A. L. Rodriguez, J. K. Shirey, A. E. Brady, T. Nalywajko, Q. Luo, et al. Discovery and Characterization of Novel Allosteric Potentiators of M1 Muscarinic Receptors Reveals Multiple Modes of Activity Mol. Pharmacol., March 1, 2009; 75(3): 577 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Lebon, C. J. Langmead, B. G. Tehan, and E. C. Hulme Mutagenic Mapping Suggests a Novel Binding Mode for Selective Agonists of M1 Muscarinic Acetylcholine Receptors Mol. Pharmacol., February 1, 2009; 75(2): 331 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Thomas, R. Mistry, C. J. Langmead, M. D. Wood, and R. A. J. Challiss G Protein Coupling and Signaling Pathway Activation by M1 Muscarinic Acetylcholine Receptor Orthosteric and Allosteric Agonists J. Pharmacol. Exp. Ther., November 1, 2008; 327(2): 365 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. K. Jones, A. E. Brady, A. A. Davis, Z. Xiang, M. Bubser, M. N. Tantawy, A. S. Kane, T. M. Bridges, J. P. Kennedy, S. R. Bradley, et al. Novel Selective Allosteric Activator of the M1 Muscarinic Acetylcholine Receptor Regulates Amyloid Processing and Produces Antipsychotic-Like Activity in Rats J. Neurosci., October 8, 2008; 28(41): 10422 - 10433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Salah-Uddin, D. R. Thomas, C. H. Davies, J. J. Hagan, M. D. Wood, J. M. Watson, and R. A. J. Challiss Pharmacological Assessment of M1 Muscarinic Acetylcholine Receptor-Gq/11 Protein Coupling in Membranes Prepared from Postmortem Human Brain Tissue J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 869 - 874. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. C. De Lorme, M. K.O. Grant, M. J. Noetzel, S. B. Polson, and E. E. El-Fakahany Long-Term Changes in the Muscarinic M1 Receptor Induced by Instantaneous Formation of Wash-Resistant Xanomeline-Receptor Complex J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 868 - 876. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Iwatsubo, S. Suzuki, C. Li, T. Tsunematsu, F. Nakamura, S. Okumura, M. Sato, S. Minamisawa, Y. Toya, S. Umemura, et al. Dopamine induces apoptosis in young, but not in neonatal, neurons via Ca2+-dependent signal Am J Physiol Cell Physiol, November 1, 2007; 293(5): C1498 - C1508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Sullivan, L. Leventhal, J. Harrison, V. A. Smith, T. A. Cummons, T. B. Spangler, S.-C. Sun, P. Lu, A. J. Uveges, B. W. Strassle, et al. Pharmacological Characterization of the Muscarinic Agonist (3R,4R)-3-(3-Hexylsulfanyl-pyrazin-2-yloxy)-1-aza-bicyclo[2.2.1]heptane (WAY-132983) in in Vitro and in Vivo Models of Chronic Pain J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1294 - 1304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. T. May, V. A. Avlani, C. J. Langmead, H. J. Herdon, M. D. Wood, P. M. Sexton, and A. Christopoulos Structure-Function Studies of Allosteric Agonism at M2 Muscarinic Acetylcholine Receptors Mol. Pharmacol., August 1, 2007; 72(2): 463 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Spalding, J.-N. Ma, T. R. Ott, M. Friberg, A. Bajpai, S. R. Bradley, R. E. Davis, M. R. Brann, and E. S. Burstein Structural Requirements of Transmembrane Domain 3 for Activation by the M1 Muscarinic Receptor Agonists AC-42, AC-260584, Clozapine, and N-Desmethylclozapine: Evidence for Three Distinct Modes of Receptor Activation Mol. Pharmacol., December 1, 2006; 70(6): 1974 - 1983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Jakubik, E. E. El-Fakahany, and V. Dolezal Differences in Kinetics of Xanomeline Binding and Selectivity of Activation of G Proteins at M1 and M2 Muscarinic Acetylcholine Receptors Mol. Pharmacol., August 1, 2006; 70(2): 656 - 666. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Galici, C. K. Jones, K. Hemstapat, Y. Nong, N. G. Echemendia, L. C. Williams, T. de Paulis, and P. J. Conn Biphenyl-indanone A, a Positive Allosteric Modulator of the Metabotropic Glutamate Receptor Subtype 2, Has Antipsychotic- and Anxiolytic-Like Effects in Mice J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 173 - 185. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Conn and C. M. Niswender mGluR7's lucky number PNAS, January 10, 2006; 103(2): 251 - 252. [Full Text] [PDF]
|
|
|
|
|
|
C. J. Langmead, V. A. H. Fry, I. T. Forbes, C. L. Branch, A. Christopoulos, M. D. Wood, and H. J. Herdon Probing the Molecular Mechanism of Interaction between 4-n-Butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the Muscarinic M1 Receptor: Direct Pharmacological Evidence That AC-42 Is an Allosteric Agonist Mol. Pharmacol., January 1, 2006; 69(1): 236 - 246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Mitsukawa, R. Yamamoto, S. Ofner, J. Nozulak, O. Pescott, S. Lukic, N. Stoehr, C. Mombereau, R. Kuhn, K. H. McAllister, et al. From The Cover: A selective metabotropic glutamate receptor 7 agonist: Activation of receptor signaling via an allosteric site modulates stress parameters in vivo PNAS, December 20, 2005; 102(51): 18712 - 18717. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Wess Allosteric Binding Sites on Muscarinic Acetylcholine Receptors Mol. Pharmacol., December 1, 2005; 68(6): 1506 - 1509. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Sur, P. J. Mallorga, M. Wittmann, M. A. Jacobson, D. Pascarella, J. B. Williams, P. E. Brandish, D. J. Pettibone, E. M. Scolnick, and P. J. Conn N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity PNAS, November 11, 2003; 100(23): 13674 - 13679. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Baker, I. P. Hall, and S. J. Hill Agonist Actions of "{beta}-Blockers" Provide Evidence for Two Agonist Activation Sites or Conformations of the Human {beta}1-Adrenoceptor Mol. Pharmacol., June 1, 2003; 63(6): 1312 - 1321. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
